Review of the Safety and Feasibility of Rapid Infusion of Rituximab-Reference-Cited by-同舟云学术

Review of the Safety and Feasibility of Rapid Infusion of Rituximab

Published:2010-03 Issue:2 Volume:6 Page:91-93
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Atmar Jill¹

Affiliation:

1. Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Abstract

Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.200001

Reference23 articles.

1. Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases

2. A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

3. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

4. Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

5. Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework;Expert Opinion on Drug Delivery;2023-02-28

2. Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting;Clinical and Translational Science;2022-11-24

3. The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe;Hematological Oncology;2022-03-17

4. Impact of electronic interventions on guideline concordant ordering of rituximab infusion rate;Journal of Oncology Pharmacy Practice;2022-02-15

5. Importance of the Infusion Order in the Treatment of Cancer;Chemotherapy Protocols and Infusion Sequence;2022